The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40).
G. Von Minckwitz
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche; Sanofi
Honoraria - Sanofi
Research Funding - GlaxoSmithKline
H. Tesch
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche; Sanofi
Honoraria - GlaxoSmithKline; Novartis; Roche; Sanofi
C. Solbach
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
K. Diedrich
No relevant relationships to disclose
M. Just
No relevant relationships to disclose
M. Clemens
No relevant relationships to disclose
C. Hanusch
No relevant relationships to disclose
I. Schrader
No relevant relationships to disclose
S. Henschen
No relevant relationships to disclose
G. Hoffmann
No relevant relationships to disclose
K. Tiemann
No relevant relationships to disclose
K. Diebold
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
C. Denkert
No relevant relationships to disclose